Merck & Co (MRK) is scheduled to report Q2 earnings on July 28, 2026. Analysts estimate EPS of $0.30 and quarterly revenue of $16.37B.
In the most recent quarter (Q1), Merck & Co reported EPS of $-1.28, beating estimates of $-1.48 by 0.14%. Revenue came in at $16.29B, exceeding the estimate of $15.86B by 0.03%.
Merck & Co has beaten EPS estimates in 8 consecutive quarters.
Over the last 4 quarters, Merck & Co has averaged an EPS surprise of 0.08% and a revenue surprise of 0.01%.
Analyze the earnings history of Merck & Co using advanced sorting and filters.
The chart below shows Merck & Co's reported EPS compared to analyst estimates over recent quarters.
The chart below shows Merck & Co's reported revenue compared to analyst estimates over recent quarters.
Merck & Co (MRK) is scheduled to report earnings on July 28, 2026. The last reported earnings were for reported on April 30, 2026 for Q1.
The Actual EPS was $-1.28, which beat the estimate of $-1.48.
The Actual Revenue was $16.29B, which beat the estimate of $15.86B.
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q1 | 2026-04-30 | $-1.28 | $-1.48 | 13.5 % |
| Q4 | 2026-02-03 | $2.04 | $2.02 | 0.99 % |
| Q3 | 2025-10-30 | $2.58 | $2.35 | 9.79 % |
| Q2 | 2025-07-29 | $2.13 | $2.01 | 5.97 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q1 | 2026-04-30 | $16.29B | $15.86B | 2.70 % |
| Q4 | 2026-02-03 | $16.40B | $16.20B | 1.24 % |
| Q3 | 2025-10-30 | $17.28B | $17.01B | 1.56 % |
| Q2 | 2025-07-29 | $15.81B | $15.85B | -0.26 % |